were searched using different search strategies and the following free text keywords: 'droperidol'; 'nausea' or 'vomiting' or 'emesis'; 'random'; and 'surgery' or 'anesthesia' or 'post-operative'. Studies reported in any language were considered. Additional trials were identified from the reference lists of retrieved reports, and review articles on PONV and droperidol, and by manually searching locally available journals on anaesthesia.
The authors do not state how the data were extracted for the review, or how many of the reviewers performed the data extraction. The cumulative incidence of PONV was extracted for two time periods, within 6 hours after surgery and within 24 hours. The data were examined separately for the adults and children.
Methods of synthesis
How were the studies combined?
The combined data were analysed using the relative risk (RR) and the numbers-needed-to-treat (NNT), both with 95% confidence intervals (CIs). For the pooled RR, a fixed-effect model was used to combine the data when there were no more than two trials, or when there was no significant heterogeneity (i.e. P>0.1). A random-effects model was used in all other situations, according to the DerSimonian and Laird method (see Other Publications of Related Interest no.2). If any cell of a sample was zero, then 0.5 was added to all cells of that sample to calculate the RR. Sensitivity analyses were undertaken by calculating the RR and NNT for the nausea and vomiting outcomes separately, for the best-documented regimens within two predefined ranges of control event rates: early outcomes within 20 and 60% of the control event rate, and late outcomes within 40 and 80% of the control event rate. There was an attempt to test the evidence for dose responsiveness using pre-set criteria (see Other Publications of Related Interest no.3).
How were differences between studies investigated?
Heterogeneity of the data was explored graphically. This showed the scatter of the event rates (incidence of PONV) with droperidol versus the event rates with control.
Results of the review
Seventy-six RCTs with 13,352 patients: 5,351 received droperidol, 3,372 received placebo or 'no treatment', and 4,629 received another anti-emetic intervention. Forty-seven trials were in adults, of which 29 were in women only. Twentynine studies were conducted in children.
The median quality score of the included trials was 3 (range: 1 to 5). The major methodological problem was the important variability in the control event rates among the trials, which may reflect differences in the underlying risk.
Qualitative analysis.
The scatter in the event rates shown for both the early and late outcomes suggested that improved efficacy was obtained with droperidol, compared with placebo. The average incidence of early nausea was 16% with droperidol and 33% with placebo. The average incidence of early vomiting was 14% with droperidol and 29% with placebo. The average incidences of late nausea were 45 and 58% with droperidol and placebo, respectively. The average incidences of late vomiting were 28 and 46% with droperidol and placebo, respectively.
Quantitative analysis.
Overall, droperidol was found to be more efficacious than placebo in preventing PONV.
In adults, the anti-nausea effect was short-lived, and there was no dose-responsiveness; for a dose of 0.25 to 0.30 mg, the NNT to prevent early nausea was 5. However, there was dose-responsiveness for both early and late anti-vomiting efficacy; the best efficacy was obtained with a dose of 1.5 to 2.5 mg, for which the NNT was 7.
In children, there was dose-responsiveness; the best efficacy was obtained with a dose of 75 microg/kg, for which the NNT to prevent early and late vomiting was 4. The next lower dose tested in children, 50 microg/kg, showed less efficacy in both the short-and long-term, although this dose was tested in a limited number of patients only. The slightly decreased efficacy at 24 hours (NNT 4.4 with 50 microg/kg versus NNT 3.8 with 75 microg/kg) may not be perceived as clinically relevant.
Adverse drug reactions.
Two children had extrapyramidal symptoms with droperidol; the NNT was 91 in children, and 408 in any patient. There was dose-responsiveness for sedation and drowsiness; the NNT was 7.8 for a dose of 2.5 mg. Droperidol prevented postoperative headache (NNT -25).
